Bosch J, Lonn EM, Jung H, et al. - No benefit of blood pressure (BP) lowering treatment was observed in the overall group, but a reduction in events in the third of participants with increased systolic BP. After cessation of all the trial medications, researchers assessed if the benefits observed during the active treatment phase were sustained, enhanced, or attenuated. Individuals were invited to participate in 3.1 further years of observation (total 8.7 years) after the randomized treatment period (5.6 years). This study’s findings demonstrate cardiovascular benefits of rosuvastatin, and BP lowering in those with increased systolic BP, in comparison with placebo continue to accrue for at least 3 years after cessation of randomized treatment in individuals without cardiovascular disease demonstrating a legacy effect.